Cheplapharm to Take over 20 Medicines and Three Sites From Sanofi
21 Articles
21 Articles
The French pharmaceutical group Sanofi will give to the German company Cheplapharm 20 medicines marketed for a long time, three production sites dedicated to the anticoagulant Lovenox and, "in return", enter its capital. The Breton factory of Ploërmel in Morbihan is part of the lot.
Sanofi and Cheplapharm have been working together since 2014. Now the French are taking part in the German company. Cheplapharm will also be producing medicines for the first time in the future.
"Cheplapharm would resume in Sanofi a selection of 20 mature medicines" including Lovenox, as well as the related sites: that of Csanyikvölgy in Hungary (about 400 employees), of Jurong in Singapore (about 100 employees) and of Ploërmel in France, in Morbihan (about 65 employees), says Sanofi in a press release. "All employees will be resumed with a firm commitment over three years", the number one French pharmaceutical company, which is current…
Pharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic Partnership
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.
Cheplapharm to take over 20 medicines and three sites from Sanofi
Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm. The partnership expands on a working relationship between the two companies, which began in 2014. The post Cheplapharm to take over 20 medicines and three sites from Sanofi appeared first on Pharmaceutical Business review.
Employees of the company Sanofi de Ploërmel (Morbihan) sound the alarm on the future of the site after the announcement of the sale to the German group Cheplapharm.
Coverage Details
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
